EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension

Joshua P Dignam iD, Smriti Sharma, Gregor Aitchison, Ayman Gebril, Ioannis Stasinopoulos iD, Sofia Laforest, Chelbi Coyle, Ruth Andrew iD, Natalie Z M Homer, Sébastien Bonnet, Sandra Breuils-Bonnet, Martin Wabitsch und 1 weitere

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Joshua P Dignam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: Obesity, Hypertension, Pulmonary, Cytochrome P-450 CYP1A1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The contribution of obesity to pulmonary arterial hypertension (PAH) pathophysiology remains poorly understood. Adipose tissue synthesises estrogens via cytochrome P450 (CYP) 19A1 (aromatase), whereas circulating estrogens are metabolised in the lung by CYP1A1. This study investigated whether obesity predisposes to PAH through enhanced estrogen synthesis and metabolism. Experimental Approach A normoxic, two‐hit, rat model of obesity‐associated pulmonary hypertension (PH) was developed, combining Sugen 5416 (Sugen, Su) with a high‐fat diet (HFD). Estrogen levels in SuHFD rat plasma and epicardial adipose tissue (EAT) from PAH patients were quantified using LC–MS/MS. CYP1A1 expression was assessed in lung and cardiac adipose tissue from SuHFD rats and PAH patients. The therapeutic potential of the CYP1A1 inhibitor hesperetin was evaluated in vivo. Complementary studies used pulmonary artery smooth muscle cells (PASMCs) from PAH patients and Simpson–Golabi–Behmel syndrome (SGBS) adipocytes. Key Results HFD‐fed rats of both sexes developed mild PH, which Sugen moderately exacerbated. EAT from PAH patients exhibited up‐regulated aromatase and CYP1A1 expression, along with elevated estrogen levels. Circulating estrone was increased in male SuHFD rats. Pulmonary CYP1A1 expression was elevated in SuHFD rats and PAH patients. Hesperetin attenuated obesity‐associated PH, reducing CYP1A1 expression in SuHFD rat lungs and PAH PASMCs. CYP1A1 induction in female SuHFD rat pericardial adipose tissue and Sugen‐treated SGBS adipocytes was also tempered. Conclusion and Implications These findings implicate augmented estrogen production by adipose tissue and elevated pulmonary CYP1A1 expression in the pathogenesis of obesity‐associated PH. CYP1A1 may represent a novel therapeutic target in obese PAH patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityHypertension, PulmonaryCytochrome P-450 CYP1A1AnimalsMaleFemaleHumansRatsRats, Sprague-DawleyDiet, High-FatMiddle AgedEstrogensAdipose TissueAdultDisease Models, Animal

Stichwörter der Autor:innen

Sugen 5416adipose tissueestrogen metabolismestrogen synthesishesperetinpulmonary hypertension

Substanzen

Cytochrome P-450 CYP1A1Estrogens

Autor:innen und Institutionen

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Centre for Microvascular Research, William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • Quebec Heart and Lung Institute Research Center, Department of Medicine, Laval University, Quebec, Canada.
  • German Center for Child and Adolescent Health (DZKJ), Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.

ORCID-Profile: Joshua P Dignam, Ioannis Stasinopoulos, Ruth Andrew

Förderung

  • British Heart Foundation
  • Medical Research Council

Zitieren

APA

Dignam, J. P., Sharma, S., Aitchison, G., Gebril, A., Stasinopoulos, I., Laforest, S., Coyle, C., Andrew, R., Homer, N. Z. M., Bonnet, S., Breuils-Bonnet, S., Wabitsch, M., & MacLean, M. R. (2026). Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension. British Journal of Pharmacology. https://doi.org/10.1111/bph.70244

Vancouver

Dignam JP, Sharma S, Aitchison G, Gebril A, Stasinopoulos I, Laforest S, et al. Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension. British Journal of Pharmacology. 2026. doi:10.1111/bph.70244

BibTeX
@article{Dignam2026,
  author = {Dignam, Joshua P and Sharma, Smriti and Aitchison, Gregor and Gebril, Ayman and Stasinopoulos, Ioannis and Laforest, Sofia and Coyle, Chelbi and Andrew, Ruth and Homer, Natalie Z M and Bonnet, Sébastien and Breuils-Bonnet, Sandra and Wabitsch, Martin and MacLean, Margaret R},
  title = {Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70244}
}
Kostenlos starten →